Related references
Note: Only part of the references are listed.Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes
Giuliana Alimena et al.
LEUKEMIA RESEARCH (2011)
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
NF-κB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia
C. Fabre et al.
ONCOGENE (2007)
Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia
G. Carvalho et al.
ONCOGENE (2007)
Bortezomib is an effective agent for MDS/MPD syndrome with 5q - anomaly and thrombocytosis
Evangelos Terpos et al.
LEUKEMIA RESEARCH (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
TM Horton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia:: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
H Zwierzina et al.
LEUKEMIA (2005)
Myelodysplastic syndromes: From pathogenesis and prognosis to treatment
P Fenaux
SEMINARS IN HEMATOLOGY (2004)
Phase I study of bortezomib in refractory or relapsed acute leukemias
J Cortes et al.
CLINICAL CANCER RESEARCH (2004)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
Share Paper
